Milestone Scientific, Inc. · AMEX:MLSS
Milestone Scientific — Investor Presentation (September 2017)
24 slides from Milestone Scientific's investor presentation, Sep 6, 2017
Slide 1: Investor Presentation
MILEST@:NE SCIEN TIFIC® INVESTOR PRESENTATION DAN GOLDBERGER- PRESIDENT & CEO OF MILESTONE SCIENTIFIC INC. tclnc. AURighs Reserved
Slide 2: Safe Harbor
NYSE MKT: MLSS SAFE HARBOR This presentation contains forward-looking statements regarding the timing and financial impact of Milestones ability to implement its business plan,expected revenues and future success. These statements involve a number of risks and uncertainties and are based on assumpti
Slide 3: Platform Technology for computerized injections
NYSE MKT: MLSS = Platform Technology for computerized injections = Can be customized for a variety of verticals = Wand Dental subsidiary demonstrates profitable growth model = Exclusive distribution with Henry Schein in US & Canada = FDA & CE approval of CompuFlo® Epidural = COMPASS pivotal trial wi
Slide 4: Redefining Injection Technology
NYSE MKT: MLSS REDEFINING INJECTION TECHNOLOGY The hypodermic syringe was invented over 160 years ago we THE PROBLEM THE SOLUTION Painless Injection Comfort Precise Injection Milestone’s Patented DPS® Dynamic Pressure Sensing Technology September 2017 MILEST@NE
Slide 5: It Began with Dental - The Wand
NYSE MKT: MLSS IT BEGAN WITH DENTAL - THE WAND® For Clinicians: For Patients: = Anesthetize a single tooth = Painless injection = Reduction in chair time = No collateral numbness = Reduced quantity of anesthetic = Faster onset of anesthesia = Fewer complications = Ergonomic grip = Reduced patient ca
Slide 6: The Wand Single Tooth Anesthesia Instrument
THE WAND ® sinctetoott ANESTHESIA INSTRUMENT NYSE MKT: MLSS = FDA and CE marketing clearance = Over 70 MM injections delivered to date = Over $10.5M in sales in 2016 = Favorable evaluations in more than 50 peer reviewed and independent clinical research reports = 21 patents around DPS® Dynamic Press
Slide 7: US Dental Distribution - Henry Schein
NYSE MKT: MLSS US DENTAL DISTRIBUTION - HENRY SCHEIN = Recentlyannounced a 10-year exclusive agreement with Henry Schein, Inc. (NASDAQ: HSIC), the world's largest provider of dental products = Henry Schein's Exclusive Products Sales Specialist Team will exclusively market. and distribute The Wand® S
Slide 8: Revenue Growth
NYSE MKT: MLSS REVENUE GROWTH ($ millions) oe ee ee june 30,2017 Revenue $ 95 $ 10.5 $ 6.2 GM% 68% 60% 65% 8 September 2017
Slide 9: The Future
THE FUTURE
Slide 10: Beyond Dental - The Medical Opportunity
NYSE MKT: MLSS BEYOND DENTAL — THE MEDICAL OPPORTUNITY = TOTAL ADDRESSABLE MARKET > $1B in the US alone & = Unique ability to identify tissue type and control flow rate 2, © Allows for wide array of medical instruments across disciplines = Completed development on first two medical instruments Te Pe
Slide 11: Total Addressable Market: >$1B in the US Alone
NYSE MKT: MLSS TOTAL ADDRESSABLE MARKET: > $1B INTHE US ALONE Procedure ApplicationArea _# Injections per Year (millions) Epidural Labor & Delivery Periop Pain Management Chronic Pain Peripheral Nerve Block Intra-articular Knees Shoulders Hips/Other Cosmetic Botox Fillers TOTAL * Company estimates d
Slide 12: Epidural Anesthesia Application
NYSE MKT: MLSS EPIDURAL ANESTHESIA APPLICATION = CompuFlo makes the procedure more reliable for the ove = Reliably identify epidural space, reducing the risk of human error Seoone canetr = Confirmation that epidural space is Identified a a\ Epil pace a September 2017
Slide 13: The CompuFlo Epidural Instrument
NYSE MKT: MLSS THE COMPUFLO® EPIDURAL INSTRUMENT = Patented DPS Technology improves clinical outcomes and patient satisfaction Control fluid flow rate =] BE Portable with battery backup ——— = Monitor pressure 510(k) #161883 Indication for Use:The CompuFlo Epidural Computer Controlled Anesthesia Syst
Slide 14: CompuFlo Epidural - Pivotal Study
NYSE MKT: MLSS COMPUFLO® EPIDURAL — PIVOTAL STUDY = Completed COMPASS Study (CompuFlo® Assessment Study), randomized, controlled, parallel group, multicenter, pivotal study = Designed to assess the safery and effectiveness of the epidural space verification = Reached enrollment of 400 patients consi
Slide 15: Intra-Articular Injection Application
NYSE MKT: MLSS INTRA-ARTICULAR INJECTION APPLICATION = Reliably and Precisely place the therapeutic agent where the physician wants it = Approved in the EU = Pursuing 510(k) clearance in the US 1s September 2017 Mitestgne
Slide 16: Cosmetic
NYSE MKT: MLSS COSMETIC = Under development for use with aesthetic injections = Fast precise, painless injections = Accurate & comfortable = stylus grip = Simple electronic records 6 September 2017 MILESTSNE
Slide 17: Investment Thesis
NYSE MKT: MLSS INVESTMENT THESIS < Wand Dental subsidiary is growing profitably continuing to prove that the technology and business model works Proprietary disposables provide recurring revenue with high margins Entering medical markets with clinically proven Indications for Use Anesthesia is appro
Slide 18: Thank You
MILEST@NE SCIENTIFIC® THANK YOU
Slide 19: Twelve Months 2016 (Audited)
NYSE MKT: MLSS TWELVE MONTHS 2016 (AUDITED) Income Statement Balance Sheet “Twelve Months En pended 31/Dec/16. 31/Dec/15_ December’! Se _ Cashandcashequvalents —$ 3,602229 $ 4194364 2G _ 2015 | otal curent assets $1271382 $11,824,151 Revenue $10,482,005 $9,491,569 | Otherassets $1735 $7385 Totalasse
Slide 20: Cap Table as of August 31, 2017
NYSE MKT: MLSS CAP TABLE AS OF AUGUST 31,2017 Issued and Outstanding 33,000,000 Options, $2.04 average strike price 3,186,782 Warrants,$2.55 average strike price 1,592,775 Preferred as converted ($7,000,000/$2.37 per share) 3,000,000 Fully Diluted Capitalization 40,779,557 20 September 2017
Slide 21: Key Statistics & Numbers as of Dec 31, 2016
NYSE MKT: MLSS KEY STATISTICS & NUMBERS AS OF DEC 31, 2016 = Ticker: MLSs = Exchange: NYSE MKT = Cash and Treasury Bil: 336M = Working Capital $77M = Total Stockholder’s Equity: 385M = Security Ownership of Management: 328% a September 2017
Slide 22: Recent Publications
NYSE MKT: MLSS RECENT PUBLICATIONS ED ASPs annua gional Anesthesiology and Acute Pain Medicine Meeting, 216 New Orleans, A Objective Epidural Space Identification with the Compufio * Epidural Instrument is Equivalent to Fluoroscopy/LOR
Slide 23: 2B
NYSE MKT: MLSS 2B September 2017
Slide 24: NYSE MKT: MLSS
NYSE MKT: MLSS 4 September 2017
Milestone Scientific — Investor Presentation (September 2017) on 6ix